Health Care [ 4/12 ] | Pharmaceuticals [ 26/74 ]
NASDAQ | Common Stock
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally.
The company offers Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC.
It also develops Surufatinib to trea pancreatic neuroendocrine tumor (NET), non pancreatic NET, and pancreatic ductal adenocarcinoma; Sovleplenib, to treat immune thrombocytopenic purpura and warm autoimmune hemolytic anemia; and Tazemetostat, a treatment for epithelioid sarcoma and follicular lymphoma; Fanregratinib that treats intrahepatic cholangiocarcinoma; and Ranosidenib, a novel dual-inhibitor of dehydrogenase-1 and isocitrate dehydrogenase-2 enzymes to treat acute myeloid leukemia (AML).
In addition, the company is developing HMPL-760, which is in phase I and II clinical trial to treat relapsed and/or refractory diffuse large B cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, and other B-NHL; HMPL-506 to treat Mixed-lineage leukemia-rearrange/rearrangement and nucleophosmin 1-mutantAML.
It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., and Epizyme, Inc., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021.
HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 28, 24 | 0.00 Increased by +100.00% | -1.08 Increased by +100.00% |
| Nov 10, 23 | 0.00 Decreased by N/A% | 0.04 Decreased by -100.00% |
| Jul 31, 23 | 0.97 Increased by +201.04% | -0.06 Increased by +1.86 K% |
| May 31, 23 | 0.00 Increased by +100.00% | -0.06 Increased by +100.00% |
| Feb 28, 23 | -1.02 Decreased by -251.72% | -1.02 |
| Nov 11, 22 | 0.00 Decreased by N/A% | -0.70 Increased by +100.00% |
| Aug 1, 22 | -0.96 Decreased by -190.91% | -0.72 Decreased by -33.33% |
| Jun 1, 22 | -0.70 Decreased by -102.25% | -0.70 |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 162.26 M Increased by +6.36% | 5.96 M Increased by +117.60% | Increased by +3.68% Increased by +116.55% |
| Sep 30, 24 | 162.26 M Decreased by -39.10% | 5.96 M Decreased by -92.92% | Increased by +3.68% Decreased by -88.38% |
| Jun 30, 24 | 152.84 M Decreased by -42.64% | 12.90 M Decreased by -84.69% | Increased by +8.44% Decreased by -73.32% |
| Dec 31, 23 | 152.84 M Decreased by -42.64% | 12.90 M Decreased by -84.69% | Increased by +8.44% Decreased by -73.32% |
| Sep 30, 23 | 152.56 M Increased by +36.00% | -33.89 M Increased by +65.77% | Decreased by -22.21% Increased by +74.83% |
| Jun 30, 23 | 266.44 M Increased by +31.87% | 84.28 M Increased by +151.75% | Increased by +31.63% Increased by +139.24% |
| Mar 31, 23 | 266.44 M Increased by +N/A% | 84.28 M Increased by +N/A% | Increased by +31.63% - |
| Dec 31, 22 | 266.44 M Increased by +92.85% | 84.28 M Increased by +416.52% | Increased by +31.63% Increased by +264.13% |